Published • loading... • Updated
SirPAD Subgroup Study at VIVA 2026 Focuses on Femoropopliteal PAD in Patients With Claudication
Summary by dailyguardian.ca
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
dailyguardian.caReposted by 
India Shorts
India ShortsSirPAD Subgroup Study at VIVA 2026 Focuses on Femoropopliteal PAD in Patients With Claudication
SURAT, India, Sept. 21, 2026 (GLOBE NEWSWIRE) — New results from the SirPAD randomized trial will be presented at VIVA 2026, October 3–6 at Bellagio Las Vegas, focusing on patients with femoropopliteal peripheral artery disease causing intermittent claudication. SirPAD randomized 1,252 patients with symptomatic infrainguinal PAD to angioplasty with a MagicTouch sirolimus-coated balloon (Concept Medical) or [...]
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
